

Remarks

In the application, Claims 20-25 are pending and subject to both a requirement for restriction and an election of species. In response to the restriction requirement, Applicants elect the variant Fc protein wherein position 247 is isoleucine, as recited in Claim 22, without traverse. Pursuant to the request of the Examiner for an election of species, Applicants also elect the CH2-CH3 domain comprising the amino acid sequence of SEQ ID NO: 1, without traverse.

Applicants respectfully request that the Examiner cancel Claims 20 and 25 without prejudice as these claims are withdrawn from consideration due to the restriction requirement and the election of species. However, Applicants reserve the right to pursue any non-elected inventions in subsequent divisional cases. No new subject matter has been added by amendment.

Pending claims which read on the elected species are Claims 21-24.

Applicants respectfully note their timely election in response to the restriction requirement dated June 27, 2008.

It is believed that no fee is required for this response; however, the Commissioner hereby is authorized to charge any requisite fee for the response to Deposit Account No. 05-0840. The Examiner is encouraged to telephone the undersigned if it would be useful to expedite any aspect of the prosecution.

Respectfully submitted,

/Robert L. Sharp/

Robert L. Sharp
Patent Counsel
Registration No. 45,609
Phone: (317) 651-1541

Eli Lilly and Company
Patent Division/RLS
P.O. Box 6288
Indianapolis, Indiana 46206-6288

July 25, 2008